The Cancer Institute of New Jersey prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated states in the nation. As a matrix and consortium cancer center that has been continuously funded by the NCI Cancer Center Support Grant (CCSG) mechanism since 1997, the Cancer Institute conducts state-of-the-art research, patient care, and outreach/education.
The Cancer Institute of New Jersey attracts investigators from a wide range of scientific disciplines to focus on cancer research.
Based on current research strengths and direction, members are now organized into six programs comprised of faculty who form cohesive, interdisciplinary groups supported by peer-reviewed grants and Cancer Institute of New Jersey shared resources. Programs are organized into three divisions: Basic Science, Clinical Science, and Public Health Science.
CINJ has six established Research Programs:
Cell Death and Survival Signaling
Program Leader: Eileen White, PhD
Genomic Instability and Tumor Progression
Program Leaders: Zhiyuan Shen, MD, PhD and Arnold Levine, PhD
Cancer Pharmacology and Preclinical Therapeutics
Program Leaders: X. F. Steven Zheng, PhD and Joseph R. Bertino, MD
Program Leaders: Joseph Aisner, MD and Bruce Haffty, MD
Carcinogenesis and Chemoprevention
Program Leaders: A-N Tony Kong, PhD and C. S. Yang, PhD
Cancer Prevention and Control
Program Leaders: Cristine D. Delnevo, PhD, MPH and Sharon Manne, PhD
Rutgers Cancer Institute of New Jersey has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has statewide authority beyond the university matrix, thus establishing an environment to foster and formalize a vision of transdisciplinary and translational research.